Liraglutide Anti-Diabetics rau Ntshav Qab Zib Tswjhwm CAS NO.204656-20-2
Product Detail
| CAS | 204656-20-2 | Molecular Formula | C172H265N43O51 |
| Molecular Luj | 3751.20 Nws | Qhov tshwm sim | Dawb |
| Kev cia khoom | Lub teeb tsis kam, 2-8 degree | Pob | Aluminium ntawv nyiaj hnab / vial |
| Purity | ≥98% | Kev thauj mus los | Cold Chain thiab txias cia khoom xa tuaj |
Cov khoom xyaw ntawm Liraglutide
Cov khoom xyaw nquag:
Liraglutide (analog ntawm tib neeg glucagon-zoo li peptide-1 (GLP-1) ua los ntawm cov poov xab los ntawm kev siv tshuab genetic recombination).
Lub npe tshuaj:
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Lwm cov khoom xyaw:
Disodium Hydrogen Phosphate Dihydrate, Propylene Glycol, Hydrochloric Acid thiab / los yog Sodium Hydroxide (raws li pH Adjusters nkaus xwb), Phenol, thiab dej rau txhaj.
Daim ntawv thov
Mob ntshav qab zib hom 2
Liraglutide txhim kho kev tswj cov ntshav qabzib.Nws txo qis kev noj zaub mov ntsig txog hyperglycemia (rau 24 teev tom qab kev tswj hwm) los ntawm kev ua kom cov tshuaj insulin tso tawm (tsuas yog) thaum xav tau los ntawm kev nce qib qabzib, ncua kev ua pa ntawm plab, thiab txo qis kev tso tawm ntawm prandial glucagon.
Nws yog qhov tsim nyog rau cov neeg mob uas cov ntshav qab zib tseem tswj tau tsis zoo tom qab qhov siab tshaj plaws ntawm cov tshuaj metformin lossis sulfonylureas ib leeg.Nws yog siv ua ke nrog metformin lossis sulfonylureas.
Nws ua raws li cov piam thaj-dependant, txhais tau tias nws yuav txhawb nqa cov tshuaj insulin tsuas yog thaum cov ntshav qabzib siab siab dua li qub, tiv thaiv "overshoot".Yog li ntawd, nws qhia qhov tsis txaus ntseeg ntawm kev pheej hmoo ntawm hypoglycemia.
Nws muaj peev xwm inhibiting apoptosis thiab stimulating regeneration ntawm beta hlwb (pom hauv kev tshawb fawb tsiaj).
Nws txo qis qab los noj mov thiab inhibits lub cev qhov hnyav nce, raws li qhia hauv kev tshawb fawb taub hau piv rau glimepiride.
Pharmacological Action
Liraglutide yog GLP-1 analogue nrog 97% kev sib txuas lus rau tib neeg GLP-1, uas tuaj yeem khi rau thiab qhib GLP-1 receptor.GLP-1 receptor yog lub hom phiaj ntawm haiv neeg GLP-1, ib qho endogenous incretin hormone uas txhawb cov piam thaj concentration-dependent insulin secretion los ntawm pancreatic β hlwb.Tsis zoo li haiv neeg GLP-1, cov tshuaj pharmacokinetic thiab pharmacodynamic profiles ntawm liraglutide hauv tib neeg yog qhov tsim nyog rau kev noj tshuaj ib hnub ib zaug.Tom qab txhaj tshuaj subcutaneous, nws cov txheej txheem ntawm kev ua haujlwm ntev suav nrog: kev sib koom ua ke ntawm tus kheej uas ua rau kom nqus tau sai;khi rau albumin;Ntau dua enzyme stability thiab yog li ntev plasma ib nrab-lub neej.
Cov kev ua ntawm liraglutide yog kho los ntawm nws cov kev cuam tshuam tshwj xeeb nrog GLP-1 receptor, uas ua rau muaj kev nce hauv cyclic adenosine monophosphate (cAMP).Liraglutide txhawb kev tsim cov tshuaj insulin hauv cov piam thaj hauv cov ntshav, thaum txo qis glucagon tso tawm ntau dhau ntawm cov piam thaj hauv cov ntshav.
Yog li ntawd, thaum cov ntshav qabzib nce siab, insulin secretion yog stimulation, thaum glucagon secretion yog inhibited.Hauv qhov sib piv, liraglutide txo qis insulin secretion thaum lub sij hawm hypoglycemia tsis cuam tshuam rau glucagon secretion.Cov txheej txheem hypoglycemic ntawm liraglutide kuj suav nrog kev ncua ntev me ntsis ntawm lub plab zom mov.Liraglutide txo lub cev qhov hnyav thiab lub cev rog los ntawm kev txo qis kev tshaib kev nqhis thiab lub zog noj.
